Observations on patents and other IP from a dual-licensed practitioner
As mentioned in just about every US newspaper, as well as on this blog, last month a company called Turing Pharmaceuticals and its apparently sociopathic CEO gained notoriety for buying…
Periodically there are reports in the news about the price of some drug being high, and the blame is usually placed on patents, particularly patents that cover not the active…
The statutory amendments to US patent law adopted in September 2011 were only the latest (if the most far-reaching) in a series of changes to US law following the major…
As reported in the previous post, the Knesset’s Constitution, Statute and Law Committee met on January 22 to discuss the bill to enable 18-month publication of Israel patent applications. Reports from…
A few minutes from now, the Knesset’s Constitution, Statute and Law Committee will continue its consideration of the bill to enable 18-month publication of patent applications. The Committee’s first hearing…
The previous post analyzed the bill for 18-month publication that will be discussed in committee at the Knesset on December 7, and explained how one of the provisions in the…
Igor Stravinsky’s The Rite of Spring describes, in musically graphic terms, the sacrificing of a young maiden as part of a pagan ritual. In recent years, the United States Trade…
Belloq: Dr. Jones. Again we see there is nothing you can possess which I cannot take away. –Raiders of the Lost Ark of the Covenant, 1982 “Of course…
In October I wrote about the paragraph IV challenge to Eli Lilly’s anti-lung cancer drug Alimta®, royalties from which had paid in full for a new $280 million chemistry building…
Yesterday the latest copy of my college alumni magazine arrived. The magazine included an article on the campus’ new chemistry building, built at a cost of about 280 million dollars,…
I’m Dan Feigelson. I’ve been practicing patent law for over 30 years. I’m also opinionated, as you may discover in reading my writings here.